Targeted expression of mutated ALK induces neuroblastoma in transgenic mice - PubMed (original) (raw)
. 2012 Jul 4;4(141):141ra91.
doi: 10.1126/scitranslmed.3003967.
Theresa Thor, Alexander Schramm, Katleen De Preter, Candy Kumps, Bram De Wilde, Andrea Odersky, Martin Peifer, Sven Lindner, Annika Spruessel, Filip Pattyn, Pieter Mestdagh, Björn Menten, Steffi Kuhfittig-Kulle, Annette Künkele, Katharina König, Lydia Meder, Sampurna Chatterjee, Roland T Ullrich, Stefanie Schulte, Jo Vandesompele, Frank Speleman, Reinhard Büttner, Angelika Eggert, Johannes H Schulte
Affiliations
- PMID: 22764207
- DOI: 10.1126/scitranslmed.3003967
Targeted expression of mutated ALK induces neuroblastoma in transgenic mice
Lukas C Heukamp et al. Sci Transl Med. 2012.
Abstract
Activating anaplastic lymphoma kinase (ALK) mutations were recently detected in most familial and 10% of sporadic neuroblastomas. However, the role of mutated ALK in tumorigenesis remains elusive. We demonstrate that targeted expression of the most frequent and aggressive variant, ALK(F1174L), is tumorigenic in mice. Tumors resembled human neuroblastomas in morphology, metastasis pattern, gene expression, and the presence of neurosecretory vesicles as well as synaptic structures. This ALK-driven neuroblastoma mouse model precisely recapitulated the genetic spectrum of the disease. Chromosomal aberrations were syntenic to those in human neuroblastoma, including 17q gain and MYCN oncogene amplification. Targeted ALK(F1174L) and MYCN coexpression revealed a strong synergism in inducing neuroblastoma with minimal chromosomal aberrations, suggesting that fewer secondary hits are required for tumor induction if both oncoproteins are targeted. Treatment of ALK(F1174L) transgenic mice with the ALK inhibitor TAE-684 induced complete tumor regression, indicating that tumor cells were addicted to ALK(F1174L) activity. We conclude that an activating mutation within the ALK kinase domain is sufficient to induce neuroblastoma development, and ALK inhibitors show promise for treating human neuroblastomas harboring ALK mutations.
Similar articles
- The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.
Infarinato NR, Park JH, Krytska K, Ryles HT, Sano R, Szigety KM, Li Y, Zou HY, Lee NV, Smeal T, Lemmon MA, Mossé YP. Infarinato NR, et al. Cancer Discov. 2016 Jan;6(1):96-107. doi: 10.1158/2159-8290.CD-15-1056. Epub 2015 Nov 10. Cancer Discov. 2016. PMID: 26554404 Free PMC article. - The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.
Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, Pei D, Sharma B, Vetharoy WR, Hallsworth A, Ahmad Z, Barker K, Moreau L, Webber H, Wang W, Liu Q, Perez-Atayde A, Rodig S, Cheung NK, Raynaud F, Hallberg B, Robinson SP, Gray NS, Pearson AD, Eccles SA, Chesler L, George RE. Berry T, et al. Cancer Cell. 2012 Jul 10;22(1):117-30. doi: 10.1016/j.ccr.2012.06.001. Cancer Cell. 2012. PMID: 22789543 Free PMC article. - Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Schönherr C, Ruuth K, Kamaraj S, Wang CL, Yang HL, Combaret V, Djos A, Martinsson T, Christensen JG, Palmer RH, Hallberg B. Schönherr C, et al. Oncogene. 2012 Dec 13;31(50):5193-200. doi: 10.1038/onc.2012.12. Epub 2012 Jan 30. Oncogene. 2012. PMID: 22286764 - Neuroblastoma models for insights into tumorigenesis and new therapies.
Kiyonari S, Kadomatsu K. Kiyonari S, et al. Expert Opin Drug Discov. 2015 Jan;10(1):53-62. doi: 10.1517/17460441.2015.974544. Epub 2014 Oct 25. Expert Opin Drug Discov. 2015. PMID: 25345447 Review. - Targeted Therapy for Neuroblastoma: ALK Inhibitors.
Schulte JH, Schulte S, Heukamp LC, Astrahantseff K, Stephan H, Fischer M, Schramm A, Eggert A. Schulte JH, et al. Klin Padiatr. 2013 Nov;225(6):303-8. doi: 10.1055/s-0033-1357132. Epub 2013 Oct 28. Klin Padiatr. 2013. PMID: 24166094 Review.
Cited by
- Targeting KDM1A in Neuroblastoma with NCL-1 Induces a Less Aggressive Phenotype and Suppresses Angiogenesis.
Sprüssel A, Suzuki T, Miyata N, Astrahantseff K, Szymansky A, Toedling J, Thole-Kliesch TM, Ballagee A, Lodrini M, Künkele A, Truss M, Heukamp LC, Mathia S, Hertwig F, Rosenberger C, Eggert A, Deubzer HE, Schulte JH. Sprüssel A, et al. J Clin Med. 2024 Oct 12;13(20):6081. doi: 10.3390/jcm13206081. J Clin Med. 2024. PMID: 39458030 Free PMC article. - Revisiting Neuroblastoma: Nrf2, NF-κB and Phox2B as a Promising Network in Neuroblastoma.
Peggion S, Najem S, Kolman JP, Reinshagen K, Pagerols Raluy L. Peggion S, et al. Curr Issues Mol Biol. 2024 Apr 6;46(4):3193-3208. doi: 10.3390/cimb46040200. Curr Issues Mol Biol. 2024. PMID: 38666930 Free PMC article. Review. - ALK upregulates POSTN and WNT signaling to drive neuroblastoma.
Huang M, Fang W, Farrel A, Li L, Chronopoulos A, Nasholm N, Cheng B, Zheng T, Yoda H, Barata MJ, Porras T, Miller ML, Zhen Q, Ghiglieri L, McHenry L, Wang L, Asgharzadeh S, Park J, Gustafson WC, Matthay KK, Maris JM, Weiss WA. Huang M, et al. Cell Rep. 2024 Mar 26;43(3):113927. doi: 10.1016/j.celrep.2024.113927. Epub 2024 Mar 6. Cell Rep. 2024. PMID: 38451815 Free PMC article. - Heat shock protein 90: biological functions, diseases, and therapeutic targets.
Wei H, Zhang Y, Jia Y, Chen X, Niu T, Chatterjee A, He P, Hou G. Wei H, et al. MedComm (2020). 2024 Jan 25;5(2):e470. doi: 10.1002/mco2.470. eCollection 2024 Feb. MedComm (2020). 2024. PMID: 38283176 Free PMC article. Review. - 17q Gain in Neuroblastoma: A Review of Clinical and Biological Implications.
Mlakar V, Dupanloup I, Gonzales F, Papangelopoulou D, Ansari M, Gumy-Pause F. Mlakar V, et al. Cancers (Basel). 2024 Jan 12;16(2):338. doi: 10.3390/cancers16020338. Cancers (Basel). 2024. PMID: 38254827 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases